Merck KGaA (MRK) Earnings Call Transcripts

58 earnings calls from February 2020 to November 12, 2026

Deutsche Boerse Xetra DE Health Care Pharmaceuticals

Merck KGaA's Latest Earnings Call - Q3 FY2026

In the third quarter of 2026, Merck & Co., Inc. reported revenues of $18.1 billion, reflecting a 5% increase year-over-year, driven by strong contributions from new products and oncology. The company achieved earnings per share (EPS) of $2.49, which includes a $0.12 charge related to a license agreement. Management raised the midpoint of their full-year revenue and EPS guidance, now expecting revenue between $66.8 billion and $67.3 billion and EPS of $2.77 to $2.82, signaling confidence in their expanding pipeline and product launches.

Reported metrics

MetricValueContext
Revenue $18.1 billion
EPS $2.49 includes a charge of $0.12 per share related to the SciBrunch license agreement
GARDASIL Sales $2 billion +14% YoY
WINREVAIR Sales $694 million +94% YoY
Operating Expenses $7.4 billion +12% YoY
Gross Margin 81.4% decreased slightly

Guidance from management

Merck has raised the midpoint of its full-year revenue guidance to between $66.8 billion and $67.3 billion, expecting growth of 3% to 4%. EPS guidance is now projected to be between $2.77 and $2.82.

What management said

Thanks, Dean. Before we begin the Q&A, I’m really glad to welcome Jannie Oosthuizen and Brian Foard, who are joining us this morning to help take questions; and just to remind everyone, Jannie is President of our Oncology business unit and also of MSD International, while Brian is President of our Specialty Pharma and Infectious Diseases business unit. I’d also ask that analysts please stick to one question each toda...
— Peter Dannenbaum, Q3 FY2026 earnings call
Thanks, Vamil, for that question. About the timing benefits we saw this quarter, let me lay out the complete picture, WINREVAIR included, so everyone has it: in the third quarter we saw a benefit of $550 million stemming from the timing of purchases. Of that amount, $200 million is tied to KEYTRUDA, and we expect it to fully unwind in the fourth quarter. $50 million is tied to WINREVAIR, which we also expect to unwin...
— Caroline Litchfield, Q3 FY2026 earnings call

What analysts pressed on

Analysts expressed concerns regarding the potential headwinds from generic competition impacting key products like BRIDION and JANUVIA in 2027. There is also apprehension about the sustainability of growth as the company approaches the KEYTRUDA LOE period.

Main topics on the call

Read the full Merck KGaA transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

About Merck KGaA

Merck KGaA (MRK) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on Deutsche Boerse Xetra and is based in DE. EarningsCalls.dev maintains a full-text archive of its earnings call transcripts — 58 calls on record spanning February 5, 2020 to November 12, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics. The latest calls are free to read; the full history is available through our REST API.

Earnings Call History

EarningsCalls.dev has 58 Merck KGaA earnings call transcripts on record, spanning February 5, 2020 to November 12, 2026. Based on this history, Merck KGaA reports quarterly. The most recent call on file is dated November 12, 2026. The full list is below — each row opens the transcript.

Ticker
MRK
Exchange
Deutsche Boerse Xetra
Country
DE
Sector
Health Care
Industry
Pharmaceuticals
Calls on record
58
First call
February 5, 2020
Most recent
November 12, 2026
Reporting cadence
quarterly
Quarter Date
Q3 FY2026 Nov 12, 2026 Read transcript →
Q3 FY2026 Oct 29, 2026 Read transcript →
Q2 FY2026 Aug 6, 2026 Read transcript →
Q2 FY2026 Aug 4, 2026 Read transcript →
Q1 FY2026 May 13, 2026 Read transcript →
Q1 FY2026 Apr 30, 2026 Read transcript →
Q4 FY2025 Mar 5, 2026 Read transcript →
Q4 FY2025 Feb 3, 2026 Read transcript →
Q3 FY2025 Nov 13, 2025 Read transcript →
Q3 FY2025 Oct 30, 2025 Read transcript →
Q2 FY2025 Aug 7, 2025 Read transcript →
Q2 FY2025 Jul 29, 2025 Read transcript →
Q1 FY2025 May 15, 2025 Read transcript →
Q1 FY2025 Apr 24, 2025 Read transcript →
Q4 FY2024 Mar 6, 2025 Read transcript →
Q4 FY2024 Feb 4, 2025 Read transcript →
Q3 FY2024 Nov 14, 2024 Read transcript →
Q3 FY2024 Oct 31, 2024 Read transcript →
Q2 FY2024 Aug 1, 2024 Read transcript →
Q2 FY2024 Jul 30, 2024 Read transcript →
Q1 FY2024 May 15, 2024 Read transcript →
Q1 FY2024 Apr 25, 2024 Read transcript →
Q4 FY2023 Mar 7, 2024 Read transcript →
Q4 FY2023 Feb 1, 2024 Read transcript →
Q3 FY2023 Nov 9, 2023 Read transcript →
Q3 FY2023 Oct 26, 2023 Read transcript →
Q2 FY2023 Aug 3, 2023 Read transcript →
Q2 FY2023 Aug 1, 2023 Read transcript →
Q4 FY2023 Jun 15, 2023 Read transcript →
Q1 FY2023 May 11, 2023 Read transcript →
Q1 FY2023 Apr 27, 2023 Read transcript →
Q4 FY2022 Mar 2, 2023 Read transcript →
Q4 FY2022 Feb 2, 2023 Read transcript →
Q3 FY2022 Nov 10, 2022 Read transcript →
Earnings Calls Nov 10, 2022 Read transcript →
Q3 FY2022 Oct 27, 2022 Read transcript →
Q2 FY2022 Aug 4, 2022 Read transcript →
Q2 FY2022 Jul 28, 2022 Read transcript →
Q1 FY2022 May 12, 2022 Read transcript →
Q1 FY2022 Apr 28, 2022 Read transcript →
Q4 FY2021 Mar 3, 2022 Read transcript →
Q4 FY2021 Feb 3, 2022 Read transcript →
Q3 FY2021 Nov 11, 2021 Read transcript →
Q3 FY2021 Oct 28, 2021 Read transcript →
Q2 FY2021 Aug 5, 2021 Read transcript →
Q2 FY2021 Jul 29, 2021 Read transcript →
Q1 FY2021 May 12, 2021 Read transcript →
Q1 FY2021 Apr 29, 2021 Read transcript →
Q4 FY2020 Mar 4, 2021 Read transcript →
Q4 FY2020 Feb 4, 2021 Read transcript →
Q3 FY2020 Nov 12, 2020 Read transcript →
Q3 FY2020 Oct 27, 2020 Read transcript →
Q2 FY2020 Aug 6, 2020 Read transcript →
Q2 FY2020 Jul 31, 2020 Read transcript →
Q1 FY2020 May 14, 2020 Read transcript →
Q1 FY2020 Apr 28, 2020 Read transcript →
Q4 FY2019 Mar 5, 2020 Read transcript →
Q4 FY2019 Feb 5, 2020 Read transcript →